A unified approach to targeting the lysosome’s degradative and growth signaling roles

Cancer Discovery

Volumn 7, Issue 11, 2017, Pages 1266-1283

  Rebecca, Vito W ^a   Nicastri, Michael C ^a   McLaughlin, Noel ^a   Fennelly, Colin ^a   McAfee, Quentin ^a   Ronghe, Amruta ^b   Nofal, Michel ^c   Lim, Chun Yan ^d   Witze, Eric ^e   Chude, Cynthia I ^a   Zhang, Gao ^b   Alicea, Gretchen M ^b   Piao, Shengfu ^a   Murugan, Sengottuvelan ^a   Ojha, Rani ^a   Levi, Samuel M ^a   Wei, Zhi ^f   Barber Rotenberg, Julie S ^e   Murphy, Maureen E ^b   Mills, Gordon B ^g   Lu, Yiling ^g   Rabinowitz, Joshua ^c   Marmorstein, Ronen ^e   Liu, Qin ^b   Liu, Shujing ^a   Xu, Xiaowei ^a   Herlyn, Meenhard ^b   Zoncu, Roberto ^d   Brady, Donita C ^e   Speicher, David W ^b   Winkler, Jeffrey D ^a,e   Amaravadi, Ravi K ^a,e   more..

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b WISTAR INSTITUTE   (United States)

^c PRINCETON UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f University Heights   (United States)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 7; MAMMALIAN TARGET OF RAPAMYCIN; MEPACRINE; S6 KINASE; ANTIMALARIAL AGENT; ANTINEOPLASTIC AGENT; CHLOROQUINE; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MEMBRANE PROTEIN; MTOR PROTEIN, HUMAN; PPT1 PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; THIOL ESTER HYDROLASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CELLULAR DISTRIBUTION; COLONY FORMATION; CONTROLLED STUDY; DNA DAMAGE; DNA METHYLATION; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LYSOSOME; MOUSE; MTT ASSAY; NONHUMAN; PINOCYTOSIS; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; DRUG EFFECT; GENETICS; MELANOMA; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROTEIN DEGRADATION; TUMOR CELL LINE;

ANIMALS; ANTIMALARIALS; ANTINEOPLASTIC AGENTS; AUTOPHAGY; CELL LINE, TUMOR; CELL PROLIFERATION; CHLOROQUINE; HUMANS; LYSOSOMES; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MELANOMA; MEMBRANE PROTEINS; MICE; MOLECULAR TARGETED THERAPY; PROTEOLYSIS; SIGNAL TRANSDUCTION; THIOLESTER HYDROLASES; TOR SERINE-THREONINE KINASES;

EID: 85032959641     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-17-0741     Document Type: Article

References (55)

1. Jiang X, Overholtzer M, Thompson CB. Autophagy in cellular metabolism and cancer. J Clin Invest 2015;125:47–54.
2. Krishna S, Palm W, Lee Y, Yang W, Bandyopadhyay U, Xu H, et al. PIKfyve regulates vacuole maturation and nutrient recovery following engulfment. Develop Cell 2016;38:536–47.
3. Sancak Y, Bar-Peled L, Zoncu R, Markhard AL, Nada S, Sabatini DM. Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. Cell 2010;141:290–303.
4. Bar-Peled L, Schweitzer LD, Zoncu R, Sabatini DM. Ragulator is a GEF for the rag GTPases that signal amino acid levels to mTORC1. Cell 2012;150:1196–208.
5. Carroll B, Maetzel D, Maddocks OD, Otten G, Ratcliff M, Smith GR, et al. Control of TSC2-Rheb signaling axis by arginine regulates mTORC1 activity. eLife 2016;5.
6. Degenhardt K, Mathew R, Beaudoin B, Bray K, Anderson D, Chen G, et al. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell 2006;10:51–64.
7. Klempner SJ, Myers AP, Cantley LC. What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoi-nositide 3-kinase pathway. Cancer Discov 2013;3:1345–54.
8. Korfel A, Schlegel U, Herrlinger U, Dreyling M, Schmidt C, von Baumgarten L, et al. Phase II trial of temsirolimus for relapsed/refrac-tory primary CNS lymphoma. J Clin Oncol 2016;34:1757–63.
9. Wolpin BM, Rubinson DA, Wang X, Chan JA, Cleary JM, Enzinger PC, et al. Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma. Oncologist 2014;19:637–8.
10. Rangwala R, Chang YC, Hu J, Algazy KM, Evans TL, Fecher LA, et al. Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma. Autophagy 2014;10:1391–402.
11. McAfee Q, Zhang Z, Samanta A, Levi SM, Ma XH, Piao S, et al. Autophagy inhibitor Lys05 has single-agent antitumor activity and reproduces the phenotype of a genetic autophagy deficiency. Proc Natl Acad Sci U S A 2012;109:8253–8.
12. Perera RM, Stoykova S, Nicolay BN, Ross KN, Fitamant J, Boukhali M, et al. Transcriptional control of autophagy-lysosome function drives pancreatic cancer metabolism. Nature 2015;524:361–5.
13. Strohecker AM, White E. Targeting mitochondrial metabolism by inhibiting autophagy in BRAF-driven cancers. Cancer Discov 2014;4: 766–72.
14. Liu J, Xia H, Kim M, Xu L, Li Y, Zhang L, et al. Beclin1 controls the levels of p53 by regulating the deubiquitination activity of USP10 and USP13. Cell 2011;147:223–34.
15. Egan DF, Chun MG, Vamos M, Zou H, Rong J, Miller CJ, et al. Small molecule inhibition of the autophagy kinase ULK1 and identification of ULK1 substrates. Mol Cell 2015;59:285–97.
16. Jennings BR, Ridler PJ. Interaction of chromosomal stains with DNA. An electrofluorescence study. Biophys Struct Mech 1983;10:71–9.
17. Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy 2016;12:1–222.
18. Ni HM, Bockus A, Wozniak AL, Jones K, Weinman S, Yin XM, et al. Dissecting the dynamic turnover of GFP-LC3 in the autolysosome. Autophagy 2011;7:188–204.
19. Klionsky DJ, Zuckerbraun B. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012;8:445–544.
20. Clarke JJ, Sokal DC, Cancel AM, Campen DB, Gudi R, Wagner VO, et al. Re-evaluation of the mutagenic potential of quinacrine dihydro-chloride dihydrate. Mut Res 2001;494:41–53.
21. Aits S, Kricker J, Liu B, Ellegaard AM, Hamalisto S, Tvingsholm S, et al. Sensitive detection of lysosomal membrane permeabilization by lysosomal galectin puncta assay. Autophagy 2015;11:1408–24.
22. Petersen NH, Olsen OD, Groth-Pedersen L, Ellegaard AM, Bilgin M, Redmer S, et al. Transformation-associated changes in sphingolipid metabolism sensitize cells to lysosomal cell death induced by inhibitors of acid sphingomyelinase. Cancer Cell 2013;24:379–93.
23. Leu JI, Pimkina J, Frank A, Murphy ME, George DL. A small molecule inhibitor of inducible heat shock protein 70. Mol Cell 2009;36:15–27.
24. Palm W, Park Y, Wright K, Pavlova NN, Tuveson DA, Thompson CB. The utilization of extracellular proteins as nutrients is suppressed by mTORC1. Cell 2015;162:259–70.
25. Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Ste-lekati E, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 2015;520:373–7.
26. Potts MB, McMillan EA, Rosales TI, Kim HS, Ou YH, Toombs JE, et al. Mode of action and pharmacogenomic biomarkers for exceptional responders to didemnin B. Nat Chem Biol 2015;11:401–8.
27. Bagh MB, Peng S, Chandra G, Zhang Z, Singh SP, Pattabiraman N, et al. Misrouting of v-ATPase subunit V0a1 dysregulates lysosomal acidification in a neurodegenerative lysosomal storage disease model. Nat Commun 2017;8:14612.
28. Zoncu R, Bar-Peled L, Efeyan A, Wang S, Sancak Y, Sabatini DM. mTORC1 senses lysosomal amino acids through an inside-out mechanism that requires the vacuolar H(+)-ATPase. Science 2011;334:678–83.
29. Slomnicki LP, Malinowska A, Kistowski M, Palusinski A, Zheng JJ, Sepp M, et al. Nucleolar enrichment of brain proteins with critical roles in human neurodevelopment. Mol Cell Proteomics 2016;15:2055–75.
30. Selvakumaran M, Amaravadi RK, Vasilevskaya IA, O’Dwyer PJ. Autophagy inhibition sensitizes colon cancer cells to antiangiogenic and cytotoxic therapy. Clin Cancer Res 2013;19:2995–3007.
31. Yang A, Rajeshkumar NV, Wang X, Yabuuchi S, Alexander BM, Chu GC, et al. Autophagy is critical for pancreatic tumor growth and progression in tumors with p53 alterations. Cancer Discov 2014;4:905–13.
32. Boone BA, Bahary N, Zureikat AH, Moser AJ, Normolle DP, Wu WC, et al. Safety and biologic response of pre-operative autophagy inhibition in combination with gemcitabine in patients with pancreatic adenocarcinoma. Ann Surg Oncol 2015;22:4402–10.
33. Keyszer G, Keysser C, Keysser M. Efficacy and safety of a combination therapy of methotrexate, chloroquine and cyclophosphamide in patients with refractory rheumatoid arthritis: results of an observational study with matched-pair analysis. Clin Rheumatol 1999;18:145–51.
34. Wangchuk S, Drukpa T, Penjor K, Peldon T, Dorjey Y, Dorji K, et al. Where chloroquine still works: the genetic make-up and susceptibility of Plasmodium vivax to chloroquine plus primaquine in Bhutan. Malaria journal 2016;15:277.
35. Barret A, Tagliavini F, Forloni G, Bate C, Salmona M, Colombo L, et al. Evaluation of quinacrine treatment for prion diseases. J Virol 2003;77:8462–9.
36. Bishop BM.Potential and emerging treatment options for Ebola virus disease. Ann Pharmacother 2015;49:196–206.
37. Salas E, Roy S, Marsh T, Rubin B, Debnath J. Oxidative pentose phosphate pathway inhibition is a key determinant of antimalarial induced cancer cell death. Oncogene 2016;35:2913–22.
38. Ellegaard AM, Dehlendorff C, Vind AC, Anand A, Cederkvist L, Petersen NH, et al. Repurposing cationic amphiphilic antihistamines for cancer treatment. EBioMedicine 2016;9:130–9.
39. Lin CW, Chen YS, Lin CC, Chen YJ, Lo GH, Lee PH, et al. Amiodarone as an autophagy promoter reduces liver injury and enhances liver regeneration and survival in mice after partial hepatectomy. Sci Rep 2015;5:15807.
40. Bowie M, Pilie P, Wulfkuhle J, Lem S, Hoffman A, Desai S, et al. Fluox-etine induces cytotoxic endoplasmic reticulum stress and autophagy in triple negative breast cancer. World J Clin Oncol 2015;6:299–311.
41. Shchors K, Massaras A, Hanahan D. Dual targeting of the autophagic regulatory circuitry in gliomas with repurposed drugs elicits cell-lethal autophagy and therapeutic benefit. Cancer Cell 2015;28:456–71.
42. Villanueva-Paz M, Cordero MD, Pavon AD, Vega BC, Cotan D, De la Mata M, et al. Amitriptyline induces mitophagy that precedes apoptosis in human HepG2 cells. Genes Cancer 2016;7:260–77.
43. Ostenfeld MS, Hoyer-Hansen M, Bastholm L, Fehrenbacher N, Olsen OD, Groth-Pedersen L, et al. Anti-cancer agent siramesine is a lys-osomotropic detergent that induces cytoprotective autophagosome accumulation. Autophagy 2008;4:487–99.
44. Cheong H, Lindsten T, Wu J, Lu C, Thompson CB. Ammonia-induced autophagy is independent of ULK1/ULK2 kinases. Proc Natl Acad Sci U S A 2011;108:11121–6.
45. Powles T, Lackner MR, Oudard S, Escudier B, Ralph C, Brown JE, et al. Randomized open-label phase II trial of apitolisib (GDC-0980), a novel inhibitor of the PI3K/mammalian target of rapamycin pathway, versus everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol 2016;34:1660–8.
46. Rodrik-Outmezguine VS, Okaniwa M, Yao Z, Novotny CJ, McWhirter C, Banaji A, et al. Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor. Nature 2016;534:272–6.
47. Sanders SS, Martin DD, Butland SL, Lavallee-Adam M, Calzolari D, Kay C, et al. Curation of the mammalian palmitoylome indicates a pivotal role for palmitoylation in diseases and disorders of the nervous system and cancers. PLoS Comput Biol 2015;11:e1004405.
48. Ma XH, Piao SF, Dey S, McAfee Q, Karakousis G, Villanueva J, et al. Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma. J Clin Invest 2014;124:1406–17.
49. Rebecca VW, Massaro RR, Fedorenko IV, Sondak VK, Anderson AR, Kim E, et al. Inhibition of autophagy enhances the effects of the AKT inhibitor MK-2206 when combined with paclitaxel and carboplatin in BRAF wild-type melanoma. Pigment Cell Melanoma Res 2014;27:465–78.
50. Zhang G, Frederick DT, Wu L, Wei Z, Krepler C, Srinivasan S, et al. Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. J Clin Invest 2016;126:1834–56.
51. Kamphorst JJ, Nofal M, Commisso C, Hackett SR, Lu W, Grabocka E, et al. Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein. Cancer Res 2015;75:544–53.
52. Goldman AR, Bitler BG, Schug Z, Conejo-Garcia JR, Zhang R, Speicher DW. The primary effect on the proteome of ARID1A-mutated ovarian clear cell carcinoma is downregulation of the mevalonate pathway at the post-transcriptional level. Mol Cell Proteomics 2016;15: 3348–60.
53. Cox J, Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol 2008;26:1367–72.
54. van Diggelen OP, Keulemans JL, Winchester B, Hofman IL, Van-hanen SL, Santavuori P, et al. A rapid fluorogenic palmitoyl-protein thioesterase assay: pre- and postnatal diagnosis of INCL. Mol Genet Metab 1999;66:240–4.
55. Wan J, Roth AF, Bailey AO, Davis NG. Palmitoylated proteins: purification and identification. Nat Protoc 2007;2:1573–84.